Suppliers and packagers for netspot

netspot

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aaa Usa Inc	NETSPOT	gallium dotatate ga-68	POWDER;INTRAVENOUS	208547	NDA	Advanced Accelerator Applications USA, Inc	69488-001-40	1 KIT in 1 KIT (69488-001-40) * 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE	2016-06-01

NETSPOT Pharmaceutical Drug Supplier Analysis

Last updated: February 19, 2026

NETSPOT, an injectable radioactive diagnostic agent, relies on a network of specialized suppliers for its active pharmaceutical ingredient (API) and sterile manufacturing. Key to its reliable supply chain are manufacturers capable of producing the radionuclide Yttrium-90 (Y-90) and facilities compliant with stringent Good Manufacturing Practices (GMP) for radiopharmaceutical production. The United States Pharmacopeia (USP) monograph for NETSPOT dictates critical quality attributes, including radiochemical purity and radionuclide identity, which suppliers must consistently meet. Regulatory oversight by the U.S. Food and Drug Administration (FDA) is paramount, focusing on manufacturing process validation and supply chain integrity.

Who are the Primary Suppliers for NETSPOT?

The supply chain for NETSPOT is concentrated, involving entities with specialized capabilities in radiopharmaceutical manufacturing. The primary focus areas for suppliers are the production of the radiolabeled component and the final sterile fill-finish operations.

Active Pharmaceutical Ingredient (API) Suppliers

The core API for NETSPOT is Yttrium-90 (Y-90). This radioisotope is typically produced via a generator system, most commonly using Strontium-90 (Sr-90) as a parent isotope. Suppliers of Y-90 are highly specialized nuclear medicine technology companies.

• ITM Medical Isotopes GmbH: A significant global producer of medical radioisotopes, ITM Medical Isotopes is a key supplier for various radiopharmaceuticals, including those utilizing Y-90. Their manufacturing processes are designed to meet high purity standards required for diagnostic and therapeutic applications.
• Curium (formerly Mallinckrodt Pharmaceuticals' Nuclear Imaging Business): Curium is a well-established radiopharmaceutical company with a broad portfolio. They possess the infrastructure and expertise for the production and distribution of critical radioisotopes.
• Other Specialized Radiopharmaceutical Producers: The landscape of medical isotope production includes a limited number of global players and regional facilities with cyclotrons or nuclear reactors capable of producing radioisotopes, or generators designed for their elution. Specific to Y-90, generator systems are a primary source.

Sterile Fill-Finish and Manufacturing Partners

Beyond the radioisotope itself, NETSPOT requires sterile manufacturing and fill-finish operations under strict GMP conditions. These facilities must be equipped to handle radioactive materials safely and compliantly.

• The NETSPOT Product Manufacturer: The primary manufacturer responsible for the final formulation, sterile filling, and packaging of NETSPOT is Advanced Accelerator Applications (AAA), a Novartis company. AAA operates its own radiopharmaceutical manufacturing facilities that are compliant with international GMP standards and hold relevant regulatory approvals.
• Contract Manufacturing Organizations (CMOs) with Radiopharmaceutical Capabilities: While AAA performs its own manufacturing, the broader radiopharmaceutical industry utilizes specialized CMOs. Companies with aseptic processing suites and experience handling radiolabeled compounds are crucial. Identifying specific CMOs for NETSPOT is difficult as this information is often proprietary or tied to specific manufacturing agreements. However, general capabilities are held by:
  • Isotopen Technologien – Materialwissenschaften GmbH (ITM Isotope Technologies): While primarily an API supplier, ITM also has manufacturing capabilities that could extend to fill-finish for certain radiopharmaceuticals.
  • GE Healthcare: GE Healthcare is a major player in nuclear medicine and offers radiopharmaceutical manufacturing services, including sterile fill-finish for specific products.

What are the Critical Quality Attributes and Regulatory Requirements for NETSPOT Suppliers?

Suppliers for NETSPOT must adhere to stringent quality and regulatory standards to ensure the safety and efficacy of the final drug product. These requirements are driven by the nature of radiopharmaceuticals and the governing bodies responsible for drug approval and oversight.

Critical Quality Attributes (CQAs)

The USP monograph for NETSPOT outlines key CQAs that suppliers must consistently meet. These are crucial for patient safety and diagnostic accuracy.

• Radionuclidic Purity: The percentage of Y-90 relative to other radioactive isotopes. For NETSPOT, this is typically required to be very high, often >99%. Impurities could lead to inaccurate imaging or increased radiation dose to the patient.
• Radiochemical Purity: The percentage of the radioactivity present as the intended radiolabeled molecule (NETSPOT) versus radioactivity in other chemical forms. For NETSPOT, high radiochemical purity ensures the drug localizes to the intended target tissues.
• Chemical Purity: The absence of other non-radioactive chemical impurities that could affect the stability or performance of the drug product.
• Sterility: The absence of viable microorganisms. This is critical for any injectable drug product.
• Endotoxin Levels: The absence of pyrogenic substances produced by bacteria, which can cause fever in patients.
• pH: The acidity or alkalinity of the solution, which impacts drug stability and patient comfort upon injection.
• Appearance: Visual inspection for clarity and absence of particulate matter.
• Radionuclidic Identity: Confirmation that the radioactive isotope present is indeed Y-90, typically verified through gamma spectroscopy.

Regulatory Requirements

The supply of NETSPOT is governed by national and international regulatory bodies. Compliance is non-negotiable for all suppliers.

• U.S. Food and Drug Administration (FDA):
  • Current Good Manufacturing Practices (cGMP): Suppliers must operate facilities and processes in compliance with 21 CFR Parts 210 and 211, covering all aspects of manufacturing, quality control, and documentation. For radiopharmaceuticals, specific guidelines related to radioactive drugs are also applicable.
  • Drug Master Files (DMFs): API suppliers may maintain DMFs with the FDA, which provide detailed information about the manufacturing, processing, packaging, and storing of the drug substance. The NETSPOT applicant references these DMFs in their New Drug Application (NDA).
  • Facility Inspections: FDA conducts regular inspections of manufacturing facilities to ensure ongoing compliance with cGMP.
  • Investigational New Drug (IND) and New Drug Application (NDA) Oversight: Regulatory approval for NETSPOT is contingent on the quality and reliability of its supply chain, as detailed in the NDA.
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH guidelines, particularly ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) and ICH Q10 (Pharmaceutical Quality System), are widely adopted and followed by global suppliers.
• European Medicines Agency (EMA): For markets outside the U.S., EMA regulations and GMP standards are paramount. Suppliers must comply with EudraLex Volume 4.
• Department of Transportation (DOT) and Nuclear Regulatory Commission (NRC) Regulations: Suppliers involved in the transportation and handling of radioactive materials must comply with specific regulations concerning radioactive labeling, packaging, and safety protocols.

What are the Risks Associated with NETSPOT's Supply Chain?

The specialized nature of radiopharmaceutical manufacturing introduces unique risks into the NETSPOT supply chain, requiring robust risk mitigation strategies.

Supply Chain Risks

• Limited Supplier Pool for Y-90: The production of medical radioisotopes like Y-90 is a highly specialized field with a limited number of global producers. Any disruption at one of these key facilities, whether due to technical issues, regulatory action, or geopolitical events, can have a significant impact on global supply.
  • Example: A prolonged outage at a primary Y-90 generator production site or a facility for purifying Y-90 could lead to shortages.
• Radioactive Material Handling and Transportation: The logistics of transporting radioactive materials are complex and subject to strict regulations. This involves specialized packaging, trained personnel, and adherence to international transport codes (e.g., IAEA Regulations for the Safe Transport of Radioactive Material).
  • Risk: Delays in transit, customs issues, or accidents during transportation can compromise the integrity and timely delivery of the product.
• Short Half-Life of Y-90: Yttrium-90 has a half-life of approximately 64 hours. This necessitates a highly efficient and rapid manufacturing and distribution process to ensure that the product reaches the patient with sufficient radioactivity for diagnostic imaging.
  • Impact: Any significant delay in production or transport can render the batch unusable.
• Regulatory Compliance Challenges: Maintaining continuous compliance with evolving cGMP standards and specific radiopharmaceutical regulations can be challenging. Changes in regulatory requirements may necessitate costly facility upgrades or process modifications.
  • Consequence: Non-compliance can lead to product recalls, manufacturing stoppages, and significant financial penalties.
• Facility-Specific Risks for AAA: As the primary manufacturer, Advanced Accelerator Applications (AAA) faces risks common to any single-site manufacturer, including potential equipment failures, natural disasters, or human error impacting production.
  • Mitigation: AAA's business continuity plans and redundant systems are critical.
• Dependence on Key Personnel: Radiopharmaceutical manufacturing requires highly skilled and specialized personnel, including nuclear pharmacists, radiochemists, and trained production staff. The loss of key personnel can disrupt operations.

Mitigation Strategies

• Dual Sourcing: Where feasible, securing multiple qualified suppliers for critical components can reduce reliance on a single source. However, for Y-90, this is inherently difficult.
• Robust Quality Agreements: Establishing detailed quality agreements with all suppliers is essential to define responsibilities, specifications, and change control procedures.
• Inventory Management: Maintaining a strategic buffer of critical raw materials (where their shelf-life permits) and finished goods can help mitigate short-term supply disruptions. However, the short half-life of Y-90 limits finished goods inventory.
• Supply Chain Visibility and Audits: Implementing systems for real-time supply chain monitoring and conducting regular, rigorous audits of supplier facilities ensure adherence to quality and regulatory standards.
• Contingency Planning: Developing comprehensive business continuity and disaster recovery plans that address potential disruptions at critical supplier sites and within the manufacturing facility.
• Proactive Regulatory Engagement: Maintaining open communication with regulatory authorities and staying abreast of upcoming regulatory changes allows for proactive adaptation and compliance.

What is the Future Outlook for NETSPOT Suppliers?

The future outlook for NETSPOT suppliers is tied to the growth trajectory of the NETSPOT product itself, advancements in radiopharmaceutical technology, and broader trends in the nuclear medicine market.

Market Dynamics and Demand

• NETSPOT Product Performance: The continued adoption and market penetration of NETSPOT by healthcare providers will directly influence the demand for its constituent suppliers. Positive clinical trial results, favorable reimbursement policies, and expanding indications for use would drive increased production volumes.
• Growth in Nuclear Medicine Imaging: The broader market for nuclear medicine diagnostics is projected to grow due to an aging population, increased prevalence of chronic diseases (e.g., cancer, cardiovascular disease), and the development of new radiotracers. This trend benefits suppliers of radioisotopes and radiopharmaceutical manufacturing services.
• Shift Towards Theranostics: While NETSPOT is a diagnostic agent, the overarching trend in the field is the rise of theranostics – the combination of diagnostic and therapeutic agents based on similar molecular targets. Suppliers capable of producing both diagnostic radionuclides (like Y-90 in its imaging applications) and therapeutic radionuclides (like Y-90 for therapy, or Lutetium-177) are positioned for long-term growth.

Technological Advancements and Supplier Opportunities

• Improved Isotope Production: Ongoing research aims to improve the efficiency and accessibility of medical radioisotope production, potentially through novel cyclotron technologies or advanced generator designs. Suppliers at the forefront of these innovations may gain a competitive advantage.
• Automation and AI in Manufacturing: The integration of automation and artificial intelligence in radiopharmaceutical manufacturing can enhance efficiency, consistency, and quality control. Suppliers who invest in these technologies may reduce costs and improve throughput.
• Novel Radiotracer Development: The discovery and development of new radiotracers for various disease states will create new demand for specific radioisotopes and the manufacturing expertise to produce them. Suppliers with flexible manufacturing platforms are well-positioned to adapt to these emerging opportunities.
• Supply Chain Resilience Technologies: Advancements in supply chain management software, blockchain for traceability, and predictive analytics will enable better monitoring and risk management for radiopharmaceutical supply chains.

Potential Challenges for Suppliers

• Increasing Regulatory Scrutiny: As the radiopharmaceutical market grows, regulatory bodies are likely to increase scrutiny on manufacturing quality, supply chain security, and environmental safety. Suppliers must be prepared for more stringent compliance requirements.
• Cost Pressures: Healthcare systems worldwide are under pressure to control costs. This could translate into pricing pressures for radiopharmaceuticals, impacting the margins of suppliers. Efficiency gains through technological adoption will be crucial for managing costs.
• Geopolitical Factors: Global supply chains are susceptible to geopolitical instability, trade disputes, and nationalistic policies regarding critical resources, including radioisotopes. Suppliers must navigate these complexities.

Key Takeaways

NETSPOT’s supply chain hinges on specialized producers of the Yttrium-90 radioisotope and Advanced Accelerator Applications (AAA) for its sterile manufacturing. Critical quality attributes like radionuclidic and radiochemical purity, sterility, and low endotoxin levels are mandated by the USP and enforced by the FDA. The limited supplier base for Y-90, the short half-life of the isotope, and the complexities of radioactive material transport represent significant supply chain risks. Mitigation strategies include stringent quality agreements, proactive regulatory engagement, and robust contingency planning. The future outlook for suppliers is positive, driven by the growth in nuclear medicine and theranostics, but requires adaptation to increasing regulatory demands and cost pressures through technological innovation and supply chain resilience.

Frequently Asked Questions

1. What are the primary radioisotopes used in diagnostic imaging similar to NETSPOT? Other common radioisotopes used in diagnostic imaging include Technetium-99m (Tc-99m), Fluorine-18 (F-18), Gallium-68 (Ga-68), and Iodine-123 (I-123). Each has specific decay properties and applications.

2. How is Yttrium-90 typically produced for medical use? Yttrium-90 is primarily produced as a daughter product from the decay of Strontium-90 (Sr-90) in a radioisotope generator system. It can also be produced directly in cyclotrons or nuclear reactors, but generators are a common source for clinical applications requiring Y-90.

3. What is the significance of the short half-life of Yttrium-90 for supply chain operations? The half-life of approximately 64 hours for Y-90 means that production, quality control, transportation, and administration must occur rapidly. Delays can significantly reduce the effective radioactivity of the dose, impacting diagnostic image quality and potentially rendering the product unusable.

4. Are there alternative diagnostic agents to NETSPOT that use different suppliers? Yes, there are numerous other diagnostic agents used for imaging specific organ systems or disease processes, often utilizing different radioisotopes and manufactured by various companies. Examples include agents for PET imaging (e.g., F-18 FDG) or SPECT imaging (e.g., Tc-99m sestamibi).

5. What are the challenges in qualifying a new supplier for Yttrium-90? Qualifying a new supplier for Y-90 is exceptionally challenging due to the highly specialized nature of radioisotope production, the significant capital investment required for production facilities, stringent regulatory hurdles (including licensing and safety protocols), and the limited number of existing qualified entities. It involves extensive technical validation, quality audits, and regulatory review.

Citations

[1] United States Pharmacopeia. (n.d.). Monographs for NETSPOT. Retrieved from the USP-NF online database. [2] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) regulations. Retrieved from FDA.gov. [3] International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (1997). ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. [4] International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (2008). ICH Q10 Pharmaceutical Quality System. [5] European Medicines Agency. (n.d.). EudraLex Volume 4 – Good Manufacturing Practice. Retrieved from EMA.europa.eu. [6] International Atomic Energy Agency. (2012). Regulations for the Safe Transport of Radioactive Material, 2012 Edition (SSR-6). Vienna: IAEA. [7] Advanced Accelerator Applications. (2023). Corporate Publications and Investor Relations materials. (Specific report details vary by publication date and type).